Glenmark Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Glenmark Pharmaceuticals (GLENMARK) reported revenue ₹3,949 Cr and net profit ₹301 Cr — revenue +22.2% YoY. For annual financials, live price and key ratios, visit Glenmark Pharmaceuticals screener.
GLENMARK Quarterly Results — Revenue, Profit & EPS Highlights
Glenmark Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View GLENMARK 52-week performance for the annual high/low range and current price position.
- Revenue of ₹3,949 Cr in Mar 2026 (-1.2% vs Jun 2026, +22.2% vs Mar 2025)
- Net Profit of ₹301 Cr in Mar 2026 (-37.7% vs Jun 2026, +7425.0% vs Mar 2025)
- EBITDA of ₹568 Cr in Mar 2026 (-27.6% vs Jun 2026)
- Operating Margin of 10.0% in Mar 2026 (-8.0pp vs Jun 2026)
- Earnings Per Share of ₹10.68 in Mar 2026 (-37.6% vs Jun 2026)
Glenmark Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLENMARK quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,949 | 3,998 | 6,204 | 3,232 | 3,086 | -1.2% | 22.2% |
| Net Profit (₹ Cr) | 301 | 483 | 610 | 4 | 47 | - | - |
| EBITDA (₹ Cr) | 568 | 784 | 1,132 | 164 | 79 | - | - |
| EPS (₹) | 10.68 | 17.11 | 21.63 | 0.16 | 1.66 | - | - |
| Operating Margin (%) | 10.0% | 18.0% | 16.0% | 5.0% | 2.0% | - | - |
GLENMARK Share Price Trend — 1-Year Movement Across Quarterly Results
Glenmark Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse GLENMARK FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLENMARK vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Glenmark Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores